ConcertAI’s deep, custom abstraction of patient real-world data and decades of scientific expertise helps clients through the regulatory process of designing and submitting successful External Control Arms.
Identify patients with rare solid tumors or hematologic malignancies
Competitive Trial Space
Limit susceptibility to competitive trial recruitment by leveraging retrospective samples
Oversample critical subgroups of interest for deeper analyses
Find, recruit, and analyze control patients in months rather than years
Infographic: External Control Arms Can Bring Life-Saving Cancer Drugs to Market Faster
Clinical Trial Challenges
Clinical trials are expensive and challenging in ordinary times. COVID-19 has made this situation much more difficult, negatively impacting clinical trial activities and delaying life-saving treatments. In response, the FDA has acted recently to create an environment to encourages novel trial designs where external control arms can thrive.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.